Janssen Pharmaceutica Inc.
www.janssen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Janssen Pharmaceutica Inc.
Japan Nods Include Torii's Vtama, Skyrizi In New Uses
Japan issues approval recommendations in new indications, including Torii's Vtama in atopic dermatitis and AbbVie's Skyrizi in ulcerative colitis. Separately, filing requirements for the use of concomitant therapies have been revised.
Janssen’s Stelara May Be Medicare Price Negotiation Savings Star
New research is gauging how much savings CMS may see on the prices of the first 10 drugs selected for negotiation.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
First Digital Therapeutic App Filed For Approval In Expanding Japan ADHD Market
A pioneering approval filing for a therapeutic app by Shionogi is set to herald expansion of ADHD therapies beyond the pill in Japan, along with growth in the pediatric segment for the disorder.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice